Anti-scarring
gene therapy
INVESTORS
SOLID SCIENCE - NEAR TERM GROWTH OPPORTUNITY
Gene therapy is one of the hottest growth areas in biotech with more than $9 Billion invested in a2018, up 64% from 2017 and 2018.
Cellastra is targeting dermal scarring, a market expected to double to35 B USD by 2025.
CELLEXA Gene Therapy applied in the wound area switches on the pproduction of natural anti-scarring peptides already found to be safe and effective in clinical studies to date.
Rather than trying to apply topical treatment for weeks or months,one treatment with CELLEXA turns on the cell factory in local cell of he targeted wound area to produce anti-scarring peptides for many weeks or months
See Investor Contacts:
